Evidence map›Paper›PMID 27381944›Full record

ArticleBiochemical pharmacology2016

Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir.

Tomas Laho, John D Clarke, Anika L Dzierlenga, Hui Li, David M Klein, Michael Goedken, Stanislav Micuda, Nathan J Cherrington

Abstract read
In one paragraph

Article in Biochemical pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Representative Rodent Models for Renal Transporter Alterations in Human Nonalcoholic Steatohepatitis.Drug metabolism and disposition: the biological fate of chemicals · 2023
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Tomas LahoUniversity of Arizona, Department of Pharmacology and Toxicology, Tucson, AZ, USA; Charles University, Department of Pharmacology, Hradec Kralove, Czech Republic.
John D ClarkeUniversity of Arizona, Department of Pharmacology and Toxicology, Tucson, AZ, USA.
Anika L DzierlengaUniversity of Arizona, Department of Pharmacology and Toxicology, Tucson, AZ, USA.
Hui LiUniversity of Arizona, Department of Pharmacology and Toxicology, Tucson, AZ, USA.
David M KleinUniversity of Arizona, Department of Pharmacology and Toxicology, Tucson, AZ, USA.
Michael GoedkenRutgers University, Department of Translational Sciences Research Pathology Services, New Brunswick, NJ, USA.
Stanislav MicudaCharles University, Department of Pharmacology, Hradec Kralove, Czech Republic.
Nathan J CherringtonUniversity of Arizona, Department of Pharmacology and Toxicology, Tucson, AZ, USA. Electronic address: cherrington@pharmacy.arizona.edu.
University of Arizona · USCharles University · CZRutgers, The State University of New Jersey · US

Funding

SOUTHWEST ENVIRONMENTAL HEALTH SCIENCES CENTERP30ES006694 · NIEHS · UNIVERSITY OF ARIZONA · PI DEAN BILLHEIMER · 1994 to 2026
$36.7M
Training in Environmental Toxicology of Human DiseaseT32ES007091 · NIEHS · UNIVERSITY OF ARIZONA · PI Nathan J Cherrington · 1985 to 2026
$10.7M
Pediatric Adverse Drug Reactions in NASHR01HD062489 · NICHD · UNIVERSITY OF ARIZONA · PI CHERRINGTON, NATHAN J · 2011 to 2015
$1.6M
Hepatoprotective Mrp3R01DK068039 · NIDDK · UNIVERSITY OF ARIZONA · PI CHERRINGTON, NATHAN J · 2005 to 2009
$1.5M
NICHD NIH HHS R01 HD062489NIDDK NIH HHS R01 DK068039NIEHS NIH HHS P30 ES006694NIEHS NIH HHS T32 ES007091
6 · The paper itself

Abstract

BACKGROUND AND

aimsAdefovir, an acyclic nucleotide reverse transcriptase inhibitor used to treat hepatitis B viral infection, is primarily eliminated renally through cooperation of glomerular filtration with active tubular transport. Nonalcoholic steatohepatitis is a variable in drug disposition, yet the impact on renal transport processes has yet to be fully understood. The goal of this study was to determine the effect of nonalcoholic steatohepatitis on the pharmacokinetics of adefovir in rats given a control or methionine and choline deficient diet to induce nonalcoholic steatohepatitis.

methodsAnimals received a bolus dose of 7mg/kg (35μCi/kg) [(3)H] adefovir with consequent measurement of plasma and urine concentrations. Inulin clearance was used to determine glomerular filtration rate.

resultsMethionine and choline deficient diet-induced nonalcoholic steatohepatitis prolonged the elimination half-life of adefovir. This observation occurred in conjunction with reduced distribution volume and hepatic levels of adefovir. Notably, despite these changes, renal clearance and overall clearance were not changed, despite markedly reduced glomerular filtration rate in nonalcoholic steatohepatitis. Alteration of glomerular filtration rate was fully compensated for by a significant increase in tubular secretion of adefovir. Analysis of renal transporters confirmed transcriptional up-regulation of Mrp4, the major transporter for adefovir tubular secretion.

conclusionsThis study demonstrates changes to glomerular filtration and tubular secretion that alter pharmacokinetics of adefovir in nonalcoholic steatohepatitis. Nonalcoholic steatohepatitis-induced changes in renal drug elimination processes could have major implications in variable drug response and the potential for toxicity.

Indexed as

AdenineAnimalsCholineDietGlomerular Filtration RateKidneyMaleMethionineNon-alcoholic Fatty Liver DiseaseOrganophosphonatesRatsRats, Sprague-DawleyReverse Transcriptase InhibitorsadefovirAdenineCholineMethionineOrganophosphonatesReverse Transcriptase InhibitorsAdefovirGFRNASHRenal elimination

Identifiers

PMID27381944
PMCPMC5393628
OpenAlexW2467370222

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.